NASDAQ: EXAS |
| Healthcare / Medical Diagnostics & Research / USA |
45.15 | +2.91 | +6.89% | Vol 3.20M | 1Y Perf -67.13% |
Jun 24th, 2022 16:00 DELAYED |
BID | 44.36 | ASK | 45.13 | ||
Open | 42.51 | Previous Close | 42.24 | ||
Pre-Market | - | After-Market | 44.87 | ||
- - | -0.28 -0.62% |
Target Price | 98.40 | Analyst Rating | Strong Buy 1.25 | |
Potential % | 117.94 | Finscreener Ranking | ★★★+ 50.92 | |
Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★★ 46.08 | |
Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★★+ 47.57 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 9.94 | Earnings Rating | Buy | |
Market Cap | 7.94B | Earnings Date | 27th Jul 2022 | |
Alpha | 0.00 | Standard Deviation | 0.15 | |
Beta | 1.24 |
Today's Price Range 42.0945.18 | 52W Range 35.34133.99 | 5 Year PE Ratio Range -54.20-28.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 21.96% | ||
1 Month | -6.77% | ||
3 Months | -32.28% | ||
6 Months | -42.20% | ||
1 Year | -67.13% | ||
3 Years | -59.49% | ||
5 Years | 27.15% | ||
10 Years | 341.78% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -21.21 | |||
ROE last 12 Months | -22.24 | |||
ROA (5Y Avg) | -4.78 | |||
ROA last 12 Months | -11.60 | |||
ROC (5Y Avg) | -14.88 | |||
ROC last 12 Months | -12.57 | |||
Return on invested Capital Q | -3.12 | |||
Return on invested Capital Y | -3.75 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 8.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-9.50 | ||||
2.23 | ||||
3.54 | ||||
364.30 | ||||
-13.60 | ||||
-1.15 | ||||
-6.33 | ||||
18.52 | ||||
8.82B | ||||
Forward PE | -10.88 | |||
PEG | -2.03 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.10 | ||||
2.50 | ||||
0.42 | ||||
0.73 | ||||
-58.00 | ||||
Leverage Ratio | 1.90 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
73.90 | ||||
-39.90 | ||||
-29.90 | ||||
-46.60 | ||||
-40.11 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.85B | ||||
10.52 | ||||
44.08 | ||||
64.93 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -1.12 | -1.04 | 7.14 |
Q04 2021 | -0.91 | -1.28 | -40.66 |
Q03 2021 | -0.89 | -0.97 | -8.99 |
Q02 2021 | -0.72 | -1.03 | -43.06 |
Q01 2021 | -1.04 | -0.18 | 82.69 |
Q04 2020 | -0.19 | -0.09 | 52.63 |
Q03 2020 | -0.51 | -0.36 | 29.41 |
Q02 2020 | -0.62 | -0.58 | 6.45 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -1.09 | 0.00 | - |
9/2022 QR | -1.10 | -3.77 | Negative |
12/2022 FY | -4.28 | 1.15 | Positive |
12/2023 FY | -3.27 | -0.93 | Negative |
Next Report Date | 27th Jul 2022 |
Estimated EPS Next Report | -1.08 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 3.20M |
Shares Outstanding | 175.95K |
Shares Float | 155.72M |
Trades Count | 41.30K |
Dollar Volume | 141.35M |
Avg. Volume | 2.24M |
Avg. Weekly Volume | 2.45M |
Avg. Monthly Volume | 2.14M |
Avg. Quarterly Volume | 2.12M |
Exact Sciences Corporation (NASDAQ: EXAS) stock closed at 45.15 per share at the end of the most recent trading day (a 6.89% change compared to the prior day closing price) with a volume of 3.20M shares and market capitalization of 7.94B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 5000 people. Exact Sciences Corporation CEO is Kevin T. Conroy.
The one-year performance of Exact Sciences Corporation stock is -67.13%, while year-to-date (YTD) performance is -41.99%. EXAS stock has a five-year performance of 27.15%. Its 52-week range is between 35.34 and 133.99, which gives EXAS stock a 52-week price range ratio of 9.94%
Exact Sciences Corporation currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 2.23, a price-to-sale (PS) ratio of 3.54, a price to cashflow ratio of 364.30, a PEG ratio of 2.32, a ROA of -11.60%, a ROC of -12.57% and a ROE of -22.24%. The company’s profit margin is -40.11%, its EBITDA margin is -29.90%, and its revenue ttm is $1.85 Billion , which makes it $10.52 revenue per share.
Of the last four earnings reports from Exact Sciences Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Exact Sciences Corporation’s next earnings report date is 27th Jul 2022.
The consensus rating of Wall Street analysts for Exact Sciences Corporation is Strong Buy (1.25), with a target price of $98.4, which is +117.94% compared to the current price. The earnings rating for Exact Sciences Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exact Sciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exact Sciences Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.90, ATR14 : 3.43, CCI20 : 0.51, Chaikin Money Flow : -0.08, MACD : -3.44, Money Flow Index : 51.25, ROC : -6.13, RSI : 49.57, STOCH (14,3) : 62.17, STOCH RSI : 1.00, UO : 55.19, Williams %R : -37.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exact Sciences Corporation in the last 12-months were: James E. Doyle (Option Excercise at a value of $214 760), James E. Doyle (Sold 2 640 shares of value $293 489 ), Jeffrey T. Elliott (Option Excercise at a value of $311 127), Jeffrey T. Elliott (Sold 45 807 shares of value $4 837 927 ), Katherine S. Zanotti (Sold 1 381 shares of value $153 439 ), Kevin T. Conroy (Option Excercise at a value of $5 851 572), Kevin T. Conroy (Sold 114 628 shares of value $10 878 114 ), Sarah Condella (Option Excercise at a value of $318 020), Sarah Condella (Sold 20 716 shares of value $1 549 462 ), Scott D. Coward (Option Excercise at a value of $622 254), Scott D. Coward (Sold 9 756 shares of value $741 613 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
CEO: Kevin T. Conroy
Telephone: +1 608 284-5700
Address: 441 Charmany Drive, Madison 53719, WI, US
Number of employees: 5 000
Thu, 28 Apr 2022 04:25 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Teladoc (TDOC) and Guardant Health (GH)
- TipRanks. All rights reserved.Thu, 28 Apr 2022 02:06 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Exact Sciences (EXAS) and Cochlear Limited (OtherCHEOF)
- TipRanks. All rights reserved.Wed, 27 Apr 2022 12:36 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Exact Sciences (EXAS) and Mednax (MD)
- TipRanks. All rights reserved.Tue, 25 Jan 2022 20:26 GMT Exact Sciences: Could Decline More in 2022
- TipRanks. All rights reserved.Thu, 20 Jan 2022 13:25 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Encompass Health (EHC)
- TipRanks. All rights reserved.Thu, 20 Jan 2022 08:45 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS) and MannKind (MNKD)
- TipRanks. All rights reserved.Thu, 20 Jan 2022 01:25 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), UnitedHealth (UNH)
- TipRanks. All rights reserved.Tue, 11 Jan 2022 18:20 GMT Exact Sciences (EXAS) Gets a Buy Rating from Leerink Partners
- TipRanks. All rights reserved.Tue, 11 Jan 2022 18:15 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and NanoString Tech (NSTG)
- TipRanks. All rights reserved.Tue, 11 Jan 2022 15:26 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), BioAtla (BCAB)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.